Last reviewed · How we verify
PIFB with adjuvants
PIFB is a polyinosinic-polycytidylic acid (poly I:C) based immunostimulatory vaccine formulation designed to activate innate and adaptive immune responses against tumor antigens.
PIFB is a polyinosinic-polycytidylic acid (poly I:C) based immunostimulatory vaccine formulation designed to activate innate and adaptive immune responses against tumor antigens. Used for Cancer immunotherapy (investigational use with various tumor types).
At a glance
| Generic name | PIFB with adjuvants |
|---|---|
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Immunostimulatory vaccine |
| Target | TLR3, TLR7/8 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PIFB (Poly-ICLC with adjuvants) functions as a toll-like receptor (TLR) agonist that stimulates pattern recognition receptors to enhance antigen presentation and T-cell activation. The adjuvant formulation is intended to boost immunogenicity and promote anti-tumor immune responses. This approach leverages innate immune activation to drive adaptive immunity against cancer cells.
Approved indications
- Cancer immunotherapy (investigational use with various tumor types)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |